At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Lorcaserin +2 moredrug
Likely dose
Lorcaserin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Lorcaserin on Cannabis Withdrawal and Self-administration
In Brief
A Phase 2 clinical trial evaluating Lorcaserin, Placebo, and 1 other intervention for Cannabis Use. Completed, enrolled 15 participants across 1 site.
Detailed Summary
In this study, the investigators are interested in testing how lorcaserin influences the effects of cannabis in a human laboratory model of cannabis use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Use
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartSep 2017
Primary CompletionMay 2021
Study CompletionDec 2021
TodayJul 2026
First PostedAug 18, 2017
Enrollment StartSep 5, 2017
Primary CompletionMay 31, 2021
Study CompletionDec 31, 2021
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.9 years ago
Interventions
Lorcaserindrug
Lorcaserin 10mg BID
Placebodrug
Placebo capsule BID
Marijuanadrug
Smoked marijuana cigarette